Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Allos Therapeutics’ Pralatrexate Demonstrates Anticancer Activity in Multiple Cancer Cell Lines
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Allos Therapeutics, Inc. has announced new data demonstrating the anticancer activity of its investigational drug, pralatrexate, in colon, ovarian, lung, prostate, and head and neck cancer cell lines.
The preclinical research further showed that the antiproliferative effects against these cancer lines were achieved at drug concentrations that are attainable in humans. These data were presented today at the American Association for Cancer Research (AACR) Annual Meeting in Denver, CO.
The results, outlined in a poster titled “Cytotoxicity of Pralatrexate, a Novel Synthetic Antifolate, in Human Cancer Cell Lines,” demonstrate anticancer activity of pralatrexate in nine of 15 human cell lines tested. Importantly, it appears from analyses of exposure time that the effect of pralatrexate is reached rapidly, within 24-72 hours. During this window, cancer cells susceptible to pralatrexate undergo apoptosis, or cell death.
“The broad anticancer activity demonstrated by pralatrexate in this in vitro study, combined with the results from prior exploratory non-small cell lung cancer clinical trials, support our view that the therapeutic potential of pralatrexate extends beyond hematological malignancies and merits further study in various types of solid tumors,” said Pablo J. Cagnoni, M.D., chief medical officer of Allos Therapeutics. “We are currently evaluating pralatrexate in solid tumor indications, including non-small cell lung cancer and bladder cancer.”
Further analysis of the data demonstrated a potential correlation between the sensitivity to pralatrexate and the expression level of folyl-polyglutamate synthetase (FPGS), an enzyme that catalyzes the addition of polyglutamate tails to folate derivatives such as pralatrexate.
The preclinical research further showed that the antiproliferative effects against these cancer lines were achieved at drug concentrations that are attainable in humans. These data were presented today at the American Association for Cancer Research (AACR) Annual Meeting in Denver, CO.
The results, outlined in a poster titled “Cytotoxicity of Pralatrexate, a Novel Synthetic Antifolate, in Human Cancer Cell Lines,” demonstrate anticancer activity of pralatrexate in nine of 15 human cell lines tested. Importantly, it appears from analyses of exposure time that the effect of pralatrexate is reached rapidly, within 24-72 hours. During this window, cancer cells susceptible to pralatrexate undergo apoptosis, or cell death.
“The broad anticancer activity demonstrated by pralatrexate in this in vitro study, combined with the results from prior exploratory non-small cell lung cancer clinical trials, support our view that the therapeutic potential of pralatrexate extends beyond hematological malignancies and merits further study in various types of solid tumors,” said Pablo J. Cagnoni, M.D., chief medical officer of Allos Therapeutics. “We are currently evaluating pralatrexate in solid tumor indications, including non-small cell lung cancer and bladder cancer.”
Further analysis of the data demonstrated a potential correlation between the sensitivity to pralatrexate and the expression level of folyl-polyglutamate synthetase (FPGS), an enzyme that catalyzes the addition of polyglutamate tails to folate derivatives such as pralatrexate.
